| 08:50-09:00 |
Opening remarks |
윤영철 (대한치매학회장) |
| |
Treating Alzheimer's disease with monoclonal antibodies, updates |
좌장: 윤영철 (중앙의대)
박기형 (가천의대) |
| 09:00-09:20 |
Elecsys AD CSF biomarker best practice sharing of other countries |
Cristiano Tunesi (Roche Diagnostics International) |
| 09:20-09:40 |
Lecanemab in Early Alzheimer’s Disease: Tau PET, Long-Term Outcomes, and Subcutaneous Formulation |
Michael Irizarry (Eisai) |
| 09:40-10:00 |
Baseline Characteristics Associated with Achieving Rapid Amyloid Plaque Clearance Following Donanemab Treatment |
Saygin Gonderten (Lilly) |
| 10:00-10:20 |
Coffee Break |
|
Plenary session I |
좌장: 최성혜 (인하의대) |
| 10:20-11:10 |
Monoclonal antibodies: how to apply the new hope in clinics |
양동원 (가톨릭의대) |
| |
Plenary session II |
좌장: 이재홍 (울산의대) |
| 11:10-12:00 |
Insights into mechanisms of ARIA from preclinical models - 20 years of research |
Donna M. Wilcock (Indiana University) |
| 12:00-13:00 |
총회 |
| 13:00-14:00 |
Poster Presentation |
|
| Oral Presentation A |
좌장: 심용수 (가톨릭의대)
이찬녕 (고려의대) |
Oral Presentation B |
좌장: 이학영 (경희의대)
박영호 (서울의대) |
| 14:00-14:12 |
Enhancement of glymphatic activity in early Alzheimer’s disease using low-intensity ultrasound treatment |
김재호 (한림대학교동탄성심병원) |
Downregulation of Mest facilitate the progression of AD pathophysiology |
조익훈 (서울시립대학교) |
| 14:12-14:24 |
Evaluation of Efficacy and Safety of Low Dose Ionizing Radiation Therapy on Alzheimer’s Disease: Interim Results of Multicenter Randomized, Single Blind, Phase II Clinical Trial |
정원규 (강동경희대학교병원) |
Identification of genetic risk loci and risk prediction for β-amyloid deposition in East Asian population |
김준표 (삼성서울병원) |
| 14:24-14:36 |
Effectiveness of personalized hippocampal network-targeted stimulation in Alzheimer’s disease: A randomized controlled trial |
정영희 (명지병원) |
Discordant plasma and PET biomarkers and its clinical consequence |
윤지환 (순천향대학교 부천병원) |
| 14:36-14:48 |
The Efficacy of a Home-Based, Augmented Reality Dual-Task Platform for Cognitive-Motor Training in Elderly Patients: A Pilot Observational Study |
윤보라 (가톨릭대학교 서울성모병원) |
White Matter Hyperintensities and Cholinergic Degeneration as Lewy Body Disease |
강성우 (세브란스병원) |
| 14:48-15:00 |
Presence of gait improvement 1 month after the CSF tap test in idiopathic normal pressure hydrocephalus |
김민주 (분당서울대학교병원) |
TDP-43 Oligomers in Neurodegenerative diseases: AD and SD. |
안성수 (가천대학교) |
| 15:00-15:10 |
Coffee Break |
| Neuropsychological frontiers for new Alzheimer’s disease treatments |
좌장: 정지향 (이화의대)
유희진 (건국대학교병원) |
Sustainable policy directions for cognitive health management in local communities |
좌장: 박건우 (고려의대)
고임석 (중앙치매센터) |
| 15:10-15:30 |
Treatment-tailored cognitive change detection |
이병화 (삼성서울병원) |
치매관리주치의 시범사업 |
최호진 (한양의대) |
| 15:30-15:50 |
Treatment-tailored ADL and behavioral change detection |
백민재 (분당서울대학교병원) |
경도인지장애 환자관리를 위한 정책 방향 |
서지원 (중앙치매센터) |
| 15:50-16:10 |
Early neuropsychological parallel intervention: Process-based cognitive training on memory |
신민영 (서울상담심리대학원대학교) |
지역 사회 인지건강증진 추구 정책 |
양영순 (대한치매학회 보험이사)
하태길 (보건복지부 노인건강과장) |
| Appropriate Use Recommendations for Patients Considered for Treatment with Lecanemab: Exclusion criteria |
좌장: 김병채 (전남의대)
김희진 (한양의대) |
국내 개발 치매 치료제 임상 연구 현황 |
좌장: 배애님 (KIST)
이건호 (조선대학교) |
| 16:10-16:30 |
An area of superficial siderosis |
장혜민 (서울대학교병원) |
Global phase3 trial of AR1001 in Early Alzheimer's Diseases: POLARIS-AD |
정재준 (아리바이오) |
| 16:30-16:50 |
>4 microhemorrhages |
서상원 (성균관의대) |
KDS2010(Tisolagiline): A novel inhibitor of aberrant GABA production in reactive astrocytes for treatment of neurodegenerative diseases |
김상욱 (뉴로바이오젠) |
| 16:50-17:10 |
Anticoagulants and tPA |
임재성 (울산의대) |
Double-blind, Placebo-controlled study of the effects of a live biotherapeutic product in preclincal Alzheimer's disease |
최강호 (전남대병원) |
| 17:10-17:30 |
Closing Remarks 및 시상식 |
